46 results
Page 2 of 3
8-K
EX-10.1
c1drkhssab4
19 Mar 19
Entry into a Material Definitive Agreement
4:56pm
8-K
EX-10.2
dm7hi1f 2oehz
19 Mar 19
Entry into a Material Definitive Agreement
4:56pm
8-K
EX-10.1
mgihb764d2v5b
26 May 17
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
vdg9p1ydfk0
13 Jun 16
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
12:00am
8-K
EX-10.1
3zz33ezx23jhoac
31 May 16
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
12:00am
8-K
EX-10.1
mibh4 dtq3r0g
31 Mar 16
ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
12:00am
S-8
EX-10.1
0z1yl
4 May 15
Registration of securities for employees
12:00am
8-K
EX-10.1
jlpifd44d6tr4ml7
15 Jan 15
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
12:00am
8-K
EX-10.1
3gpq9c2j2whffn
15 Oct 14
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
12:00am
8-K
EX-10.1
egms1z7mia54e3arby8
26 Jun 14
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
5eu3nctdm
20 Mar 14
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
12:00am
8-K
EX-10.1
ccr8k9
5 Feb 14
Entry into a Material Definitive Agreement
12:00am
10-12G/A
EX-10.7
h92wiscfd9 fpmmkp
24 Dec 13
Registration of securities (amended)
12:00am
10-12G/A
EX-10.5
21pa7b oxp5ilr58rbu
21 Nov 13
Registration of securities (amended)
12:00am